Showing results (181-190 of 263) with videos related to

Sort By:
Pageof 27
International Journal of Molecular Medicine|September 22, 2000
Charcot-Marie-Tooth disease type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP): reliable detection of the CMT1A duplication and HNPP deletion using 8 microsatellite markers in 2 multiplex PCRsP Seeman, R Mazanec, J Zidar, et al.
The Journal of Allergy and Clinical Immunology|May 10, 2001
Idiopathic environmental intolerance: increased prevalence of panic disorder-associated cholecystokinin B receptor allele 7K Binkley, N King, N Poonai, et al.
Neurology|August 25, 2004
Hearing loss as the first feature of late-onset axonal CMT disease due to a novel P0 mutationP Seeman, R Mazanec, K Huehne, et al.
Journal of Medicinal Chemistry|March 1, 1990
A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptorsM R Seggel, M Y Yousif, R A Lyon, et al.
Archives of Neurology|October 1, 1982
Reversible drug-induced parkinsonism. Clinicopathologic study of two casesA H Rajput, B Rozdilsky, O Hornykiewicz, et al.
Archives of General Psychiatry|June 6, 2000
A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancyS Kapur, R Zipursky, C Jones, et al.
Neurogenetics|August 6, 2013
Mosaicism for GJB1 mutation causes milder Charcot-Marie-Tooth X1 phenotype in a heterozygous man than in a manifesting heterozygous womanI Borgulová, R Mazanec, I Sakmaryová, et al.
Molecular Pharmacology|July 1, 1983
Molecular size of the canine and human brain D2 dopamine receptor as determined by radiation inactivationL Lilly, C M Fraser, C Y Jung, et al.
Acta Psychiatrica Scandinavica|March 11, 2004
Does nicotine affect D2 receptor upregulation? A case-control studyS Silvestri, J C Negrete, M V Seeman, et al.
Journal of Medicinal Chemistry|December 1, 1991
(+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationshipJ L Neumeyer, N Baindur, H B Niznik, et al.
Pageof 27